Meeting
2011 ASCO Annual Meeting
Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial.
Authors
P. E. Goss
Massachusetts General Hospital, Boston, MA
P. E. Goss , J. N. Ingle , J. Ales-Martinez , A. Cheung , R. T. Chlebowski , J. Wactawski-Wende , A. McTiernan , J. Robbins , K. Johnson , L. Martin , E. Winquist , G. Sarto , J. E. Garber , C. J. Fabian , P. Pujol , E. Maunsell , P. Farmer , K. A. Gelmon , D. Tu , H. Richardson
Organizations
Massachusetts General Hospital, Boston, MA, Mayo Clinic, Rochester, MN, Hosp Ruber Internacional, Madrid, Spain, Universtiy Health Network, Toronto, ON, Canada, Harbor-UCLA Medical Center, Torrance, CA, University of Buffalo, Buffalo, NY, Fred Hutchinson Cancer Research Center, Seattle, WA, University of California, Davis, Sacramento, CA, University of Tennessee Health Science Center, Memphis, TN, George Washington University School of Medicine, Washington, DC, London Health Sciences Centre, London, ON, Canada, Center for Women's Health and Health Research, Madison, WI, Dana-Farber Cancer Institute, Boston, MA, Kansas University Medical Center, Kansas City, KS, CHU-Hopital Arnaud de Villeneuve, Montpellier, France, Laval University, Quebec City, QC, Canada, Queen's University Pathology and Molecular Medicine, Kingston, ON, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada, NCIC Clinical Trials Group, Kingston, ON, Canada
Research Funding
NIH
Background: Limited efficacy and serious toxicities have limited uptake of tamoxifen or raloxifene as preventatives of breast cancer. Aromatase inhibitors (AIs) prevent contralateral breast cancers more than tamoxifen in adjuvant trials and have fewer serious side effects. This is the first report of an AI used in primary prevention. Methods: NCIC CTG MAP.3 is a randomized trial designed to detect a 65% reduction in annual incidence of invasive breast cancer (IBC) on exemestane (E) versus placebo (P). Eligible postmenopausal women had ≥ one of the following risk factors: Gail score >1.66%, prior ADH, ALH, LCIS or DCIS with mastectomy, age over 60. Health-related and menopause-specific quality of life (QOL) were assessed by SF-36 and MENQOL questionnaires. Results: From 2004-2010, 4,560 women were randomized: age 62.5 yrs (37-90); Gail Score 2.3 % (0.6-21); BMI 28.0 kg/m2 (15.9-65.4). Risk factors included: age >60 yrs (49%); Gail score >1.66 (40%); and prior ADH, ALH, LCIS or DCIS with mastectomy (11%). At median follow-up of 35 months there were 11 IBCs on E and 32 on P (annual incidence 0.19% vs 0.55%; HR= 0.35, 95% CI 0.18-0.70, p = 0.002); ductal (10E/27P), lobular (1E/5P). Most tumors were ER positive (7E/27P); Her2/neu negative (10E/26P); TNM stage T1 (8E/28P), N0 (7E/22P), M0 (11E/30P). E was superior in all subgroups: by Gail score, age, BMI, prior LCIS and DCIS. The annual incidence rate of IBC or DCIS was 0.35% E and 0.77% P (HR=0.47;95% CI 0.27-0.79; p = 0.004) based on 64 IBCs or DCISs (20E/44P). Clinical bone fractures, osteoporosis, hypercholesterolemia or cardiovascular events were equal in both arms. No clinically meaningful differences in QOL were detected. Conclusions: Exemestane significantly reduced invasive and pre-invasive breast cancers in postmenopausal women at increased risk for breast cancer with no serious toxicities. Exemestane should be considered a new option for primary prevention of breast cancer. Supported by the Canadian Cancer Society; Pfizer Inc. PEG supported in part by Avon Foundation.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Oral Abstract Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
Prevention
Clinical Trial Registration Number
NCT00083174
Citation
J Clin Oncol 29: 2011 (suppl; abstr LBA504)
Abstract #
LBA504
Abstract Disclosures
Similar Abstracts
Abstract
2022 ASCO Annual Meeting
Low-dose tamoxifen for breast cancer prevention in patients with ductal carcinoma in situ (DCIS) and atypical lesions: A real-world experience.
First Author: Rima Patel
Abstract
2022 ASCO Annual Meeting
A prospective decision impact study to evaluate the utility of the Oncotype DX Breast DCIS score assay in selecting patients with ductal carcinoma in situ (DCIS) following breast conservation surgery (BCS) for radiotherapy.
First Author: Mitchel Barry
Abstract
2022 ASCO Annual Meeting
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
First Author: Thomas Meyskens
Abstract
2024 ASCO Genitourinary Cancers Symposium
Stereotactic intensity modulated radiotherapy after radical prostatectomy (SCIMITAR): Two-year quality of life and toxicity outcomes of a multicenter phase II trial.
First Author: John Nikitas